SVMPharma has recently collected real-world data in the UK (ICE-UK) and Portugal (ICE-PT) for DMO patients looking at the effectiveness of fluocinolone acetonide intravitreal implant (LUVIEN®). This has led to successful outcomes leading to multiple publications to presentations in a major European congress in 2017 and 2018
Chart notes
Treatment data
Align with KOLsSVMPharma’s innovative RWE solutions
Chart note is a rich and valuable source of RWE data
SVMPharma’s Treatment Evaluator tool helps collect this data
Real-world data helps inform treatment pathways and standard of care
SVMPharma’s RWE helps track comparator outcomes and routine clinical practices
Real-world data collection backed by KOLs
SVMPharma ensures real-world data is clinically relevant by engaging with KOLs
Reference
- (1) Currie CJ. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Current Medical Research and Opinion 33:sup2, pages 33-43.
- (2) Holden SE. Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. Current Medical Research and Opinion 33:sup2, pages 5-17.
- (3) Holden SE. Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema. Current Medical Research and Opinion 33:sup2, pages 45-52.
- (4) Currie CJ. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. Current Medical Research and Opinion 33:sup2, pages 19-31.
- (5) C. Currie, S. Holden, D. Owens. Evaluation of the clinical effectiveness in routine practice of the fluocinolone acetonide intravitreal implant in patients with diabetic macular oedema. Euretina 2017
- (6) A. Carneiro, A. Meireles, J. Castro Sousa, C. Teixeira. A retrospective cohort study of the clinical outcomes of ILUVIEN® in four ophthalmology centres in Portugal: The results of the ILUVIEN® clinical evidence study in the Portugal (ICE-PT). Euretina 2018.
Acknowledgements
The presentations in Euretina were written by Alimera Sciences Limited in consultation with the respective co-authors 5-6
The presentations in Euretina were written by Alimera Sciences Limited in consultation with the respective co-authors 5-6